Incidence of ischemic cardiovascular events in the maraviroc clinical development program

Maraviroc (MVC), a CCR5 antagonist, does not appear to adversely affect serum lipids and may decrease LDL cholesterol in dyslipidemic subjects. The CCR5-del32 polymorphism, resulting in reduced (heterozygous) or absent (homozygous) CCR5 expression, is associated with reduced risk of cardiovascular disease. An early imbalance of cardiovascular adverse events was noted in the MVC phase 2b development program at 24 weeks. We investigated the longer term risk of cardiovascular events in MVC recipients in the development program. The D:A:D study and other cohorts have reported an incidence of 3.6/1000 PY for myocardial infarction (MI) among patients on HAART. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P65 Cite this article as: Portsmouth et al.: Incidence of ischemic cardiovascular events in the maraviroc clinical development program. Journal of the International AIDS Society 2010 13(Suppl 4):P65. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113070/